The inducible co-stimulator (ICOS, CD278) is essential to the efficient development of normal and pathological immune reactions. Since ICOS-deficient mice have enhanced susceptibility to experimental allergic encephalomyelitis (EAE), we have functionally analyzed a CD4
population comprising 6-15% of all CD4
1 T cells in secondary lymphoid organs of unmanipulated wild-type mice and checked for their ability to suppress EAE. In C57BL/6 mice, CD4
1 ICOS 1 cells were a major source of cytokines including IFN-g, IL-2, IL-4, IL-10 or IL-17A. Upon activation, these cells showed preferentially enhanced production of IL-4 or IL-10 but inhibited IFN-g production. In contrast, CD4
1 ICOS 2 cells mainly produced IFN-g. Interestingly, CD4 1 ICOS 1 cells partially suppressed the proliferation of CD4
1 ICOS 2 or CD4 1 CD25 2 lymphocytes 'in vitro' by an IL-10-dependent mechanism. Furthermore, CD4
1 ICOS 1 activated and expanded under appropriate conditions yielded a population enriched in cells producing IL-10 and T h 2 cytokines that also suppressed the proliferation of CD4 1 CD25 2 lymphocytes. CD4
Introduction
Antigen activation of naive T lymphocytes needs two signals: one mediated by TCR ligation and second signal delivered by ligands of non-clonally distributed molecules generically termed co-stimulators. CD28 is the main co-stimulatory molecule for T lymphocytes. Whereas most T lymphocytes constitutively express CD28, the products of pathogenic microorganisms or inflammation regulate the expression of the CD28 ligands B7-1 and B7-2 by antigen-presenting cells (APC). In addition to CD28, there are a number of distinct co-stimulatory molecules of T cells fulfilling specific roles. Inducible co-stimulator (ICOS, CD278) is a co-stimulatory molecule structurally and genetically related to CD28 and CD152 (CTLA-4). ICOS was initially characterized as a molecule favoring T cell proliferation and the production of IL-4 and IL-10, but not IL-2 (1, 2). Furthermore, data from models 'in vitro' suggested that ICOS was linked to T h 2 effector function and differentiation (3). In addition, ICOS-deficient mice had enhanced T h 1 responses 'in vivo', and their lymphocytes produced high amounts of T h 1 lymphokines like IFN-c and low amounts of the T h 2 lymphokines IL-4, IL-5 or IL-10 (4-6). Recently, it has been shown that ICOS directly fosters early IL-4 secretion by naive T cells and T h 2 differentiation by a mechanism involving the transcription factors NFATc and c-Maf (7) and enhances IL-4R-mediated induction of GATA-3 (8) . Moreover, ICOS expression is higher in activated T cells from strains with T h 2-biased responses (i.e. BALB/c), than in cells from T h 1-biased strains like C57BL/6, possibly mediated by higher IL-4 production and GATA-3 induction upon TCR-mediated activation (9, 10) . Whereas these data link ICOS to T h 2 differentiation, ICOS co-stimulation can also enhance the secretion of T h 1 lymphokines like IFN-c or tumor necrosis factor-a in vitro (9, 11, 12) . Furthermore, interaction of ICOS with its ligand B7-h favors the development of different T h 1-mediated immune reactions in vivo, including anti-viral (13) , delayed hypersensitivity (14) , autoimmune (15, 16) or anti-protozoan responses (17) and allograft rejection (18) . The role of different cell subsets in these different effects of ICOS is unclear, and particularly, the role of a naturally occurring population of CD4 + ICOS + T cells. Such cells have been detected in most peripheral lymphoid organs, and their proportion is particularly high in the Peyer's patches of mice or the tonsils of humans (1, 3, 19) . In 6-month-old BALB/c mice, it has been shown that these cells possess a strong effector potential, including most cells producing high amounts of IL-10 in unmanipulated mice (20) . Intriguingly, data by two of us (C. D. and R. F.) showed that ICOS-deficient mice developed stronger experimental allergic encephalomyelitis (EAE) to rat myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 than wild-type mice (4) . Furthermore, in a different experimental system, it was observed that blocking ICOS interactions at the induction phase of the response to proteolipid protein markedly enhanced the severity of the EAE developed by SJL mice (15) . One likely explanation for these effects would be the existence of a population of ICOS + cells actively suppressing EAE or the importance of ICOS for the in vivo function of distinct regulatory T (Tr) cell populations, as shown in experimental models of asthma (21) or diabetes (22) . ICOS-expressing cells with Tr activity, producing or not IL-10, have been also induced in vitro (23) (24) (25) . However, the relationship between these different Tr cells is unclear, as is the relationship between the ICOS + sub-population present in secondary lymphoid organs of normal mice and the Tr activity acting in specific organs in autoimmune diseases like diabetes (22) .
In this study, we have addressed the functional importance of the naturally occurring population of mouse CD4 + ICOS + T lymphocytes, as compared with the ICOS À cells becoming ICOS + only after TCR activation. Our data show that the ICOS co-stimulus can alter the T h 2/T h 1 profile of CD4
+ ICOS + cells differentiated in vitro and that this population, expanded or not in vitro, suppresses the proliferation of CD4
+ ICOS À or CD4 + CD25 À T lymphocytes. In agreement with these effects, transfer of freshly isolated or in vitro expanded ICOS + cells to ICOS-deficient C57BL/6 mice reduced the severity of EAE induced by immunization with rat MOG peptide 35-55. In addition, transfer of these cells enhanced IL-10 secretion and reduced IL-17A secretion by antigen-activated cells from mice undergoing EAE.
Methods

Mice
Mice from the strains BALB/c, C57BL/6 and B10.BR were bred under specific pathogen-free conditions in the animal care facility of the Centro de Investigaciones Biológicas from stock purchased from Charles River. ICOS-deficient mice with C57BL/6 background were bred under the same conditions from stock provided by Richard A. Flavell. C57BL/6 CD28 À/À mice were purchased from The Jackson Laboratory. Mice aged 8-14 weeks old were used throughout the experiments. All experimental procedures were performed according to established institutional and national guidelines.
Antibodies mAbs used in cell isolation and culture experiments were anti-CD3 YCD3-1 (26), anti-CD4 GK1.5 (27) , anti-CD8 53-6.72 (28) , anti-CD11b M1/70 (29) , anti-mouse/human ICOS C398.4A (2, 30), anti-CD28 37.51 (31) , anti-class II MHC 10.2. 16 (32) and Y-3JP (33), anti-mouse IL-4 11B11 (34) and anti-mouse IFN-c XMG 1.2 (35). They were used as protein A-or protein G-purified preparations of hybridoma supernatants. Anti-mouse IL-10 (JES5-2A5) was from eBioscience. Anti-ICOS-biotin, anti-ICOS-FITC and anti-CD4-FITC conjugates were obtained in our laboratory. Anti-mouse IL-10R (anti-CD210; clone 1B1.3a) and anti-CD25-biotin (7D4) were from BD Biosciences. Staining of FoxP3 was performed with FITC-or PE-coupled anti-FoxP3 antibodies (antimouse/rat FoxP3 staining set, eBioscience) according to the manufacturer's instructions.
Cell separation
Cell suspensions of pooled spleens and lymph nodes from male or female mice aged 2-6 months were prepared and passed through 30-lm filters to remove clumps. To isolate CD4
+ ICOS + cells, the cells were washed and incubated with anti-CD8, anti-CD11b and anti-class II MHC antibodies in the cold. After washing, the CD4 + cells were obtained by negative selection by passing the cell suspension over mouse Ig-anti-Ig columns (36) . Alternatively, negative selection of CD4 + lymphocytes was performed by immunomagnetic selection using Miltenyi Biotech (Bergisch Gladbach, Germany) magnetic cell sorting (MACS) reagents as specified by the manufacturer. Then, the cells were stained with anti-ICOS-FITC mAb and positively selected with LS columns and MACS using anti-FITC beads (Miltenyi Biotech), according to the manufacturer's instructions. + cells that were positively selected as above and then stained with biotinylated anti-CD25 (7D4) plus avidin-PE.
Cell culture and activation
Activation of CD4
+ T lymphocytes was performed by incubation of cells in 24-well culture plates (Costar) previously coated with antibodies (anti-CD3 plus anti-ICOS or irrelevant antibody; 20 lg ml À1 each in PBS). Wells received 10 6 cells in 1 ml of Click's medium supplemented with 10% heatinactivated fetal bovine serum (culture medium). Lymphokine secretion was determined from supernatants taken at 72 h of culture. For expansion of the activated cells, the cells were activated for 3 days, resuspended, washed and incubated at 2 3 10 5 cells ml À1 for further 7 days in culture medium supplemented with 10 U ml À1 mouse IL-2. Then, the expanded cells were analyzed for intracellular cytokine content or for their suppressive potential in standard Tr assays.
Tr assays in vitro
Tr assays were performed in 0. The assays were performed according the instructions of the supplier and developed using Extravidin-HRP (Sigma) and Sigma-fast o-phenylenediamine substrate (Sigma). Cytokine content was calculated from reference standard curves set up with recombinant cytokines. Cytokines in the supernatants of antigen-activated cells were detected using the RayBio Mouse Cytokine Antibody Array I (Raybiotech, Inc., Norcross, GA), as recommended by the manufacturer. Chemoluminiscence signal was recorded using a LAS-3000 Image Reader (Fuji), and optical density (OD) was analyzed using the NIH Image application. The OD of internal positive controls was considered as 100%.
Intracellular cytokine staining
It was performed essentially as described in Foster and Prussin (40) . Cells were washed and re-suspended at 2 3 10 6 ml À1 in culture medium and stimulated with 20 ng ml À1 phorbol dibutyrate (PDB; Sigma-Aldrich) plus 1 lM ionomycin (Calbiochem) for 1.5 h. Brefeldin A (10 lg ml À1 ; Sigma-Aldrich) was added, and the cells were incubated for further 3.5 h, washed and fixed for 5 min at room temperature with 4% paraformaldehyde in PBS. After stopping the fixation with ice-cold 0.1% BSA in PBS/0.1% azide, the cells were washed with 0.1% saponin (Sigma-Aldrich) in PBS/ 0.1% BSA/10 mM HEPES/azide (PBS/saponin) and blocked at 4°C for 30 min with 5% non-fat milk in PBS/saponin. Then, the cells were stained with PE-, Alexa Fluor 647-, DyLight 649-(Pierce) or FITC-coupled antibodies in 5% non-fat milk in PBS/saponin for 30 min in the cold. After washing three times with PBS/saponin, the cells were analyzed with FACScan (Coulter Electronics) or FACSCalibur (BD Biosciences) flow cytometers. The antibodies used were PE-coupled anti-IL-2 (JES6-5H4), anti-IL-4 (11B11) and anti-IL-10 (JES5-16E3); Alexa Fluor 647-coupled anti-IL-17A from BD Biosciences; FITC-or DyLight 649-coupled anti-IL-4 (11B11) and FITC-coupled anti-IFN-c (XMG 1.2), prepared in our laboratory by standard methods. As negative controls, PE-or FITC-conjugated isotype control mAb or blocking with excess unlabeled cytokine-specific antibodies were used with similar results.
EAE induction with MOG peptide
Rat MOG peptide 35-55 (sequence MEVGWYRSPFSRVVH-LYRNGK) was synthesized in the Protein Chemistry facility of the Centro Nacional de Microbiología, Instituto de Salud Carlos III, and was >90% pure as assessed by HPLC and mass spectrometry. EAE was induced in 8-to 12-week-old female mice as described (41) . Briefly, C57BL/6 ICOS À / À mice received in one flank a subcutaneous injection of 0.2 ml emulsion containing 300 lg MOG peptide in incomplete Freund's adjuvant (Sigma), supplemented with 500 lg of heat-killed Mycobacterium tuberculosis (Difco, Detroit, MI). Pertussis toxin (List Biological, Campbell, CA, 500 ng in 0.2 ml of PBS) was injected intra-peritoneally (i.p.) after MOG immunization and 48 h later. The injection of MOG peptide in CFA was repeated in the other flank after 1 week. The mice were observed for clinical signs and EAE scored on a scale of 0-5 with gradations of 0.5 for intermediate scores (41) , as follows: 0, no clinical signs; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; 4, hind and fore limb paralysis and 5, death. The average day of disease onset was calculated by averaging the first day of clinical signs for each mouse in one group. The average maximum disease score was determined by averaging the highest score achieved by each individual mouse. The disease index was calculated by adding all the daily average disease scores and the result was divided by the average day of disease onset of each group and multiplied by 100 (41) .
Results
Expression of ICOS by a sub-population of normal CD4 + cells
Previous data in EAE models suggested that ICOS + T cells present in non-immunized mice might prevent the development of the disease (4, 15). As we used C57BL/6 or B10.BR mice in the analysis of ICOS in different experimental models, we checked for possible strain differences in the levels of ICOS expressed by spleen CD4 + ICOS + T cells, as has been observed in activated cells (9, 10) . In our hands, the + ICOS + cells were activated with plate-bound anti-CD3 antibodies 6 anti-ICOS antibodies, and lymphokine production was determined at 72 h of culture ( Fig. 2A) . In these conditions, CD4
+ ICOS + cells were a major source of secreted IL-2, IL-4, IL-10 or IFN-c upon CD3 or CD3 plus ICOS activation ( Fig. 2A) . On the other hand, CD4
+ T cells depleted of ICOS + cells produced clearly reduced amounts of IL-2 or IL-10, and secretion of IL-4 was negligible. In contrast, IFN-c secretion by CD4 + ICOS À cells was similar or higher than that of CD4 + ICOS + cells ( Fig. 2A) . Unseparated CD4 + T cells showed an intermediate behavior, and ICOS co-stimulated the secretion of all the lymphokines analyzed, although the levels of secreted IL-2, IL-10 and, particularly, IL-4 were low in the T h 1-prone mice used ( Fig. 2A and data not shown).
These differences reflect the differences between CD4
+ ICOS À and CD4 + ICOS + cells in terms of the intra-cytoplasmic cytokines present in the cells before (Fig. 2B) + ICOS + cells also included most cells able of producing the pro-inflammatory cytokine IL-17A. In the activation conditions used, these cells did not expand or differentiate efficiently in vitro (Fig. 2B and C and data not shown).
ICOS + cells suppress the proliferation of CD4 + T lymphocytes
Recent data indicate that ICOS-dependent cells with Tr activity can be generated in different experimental models (21) (22) (23) 45) . Although they show clear differences in terms of CD69, CD25 or FoxP3 expression, these Tr cells share the properties of being inhibited by blocking ICOS-B7h interactions and of producing high amounts of IL-10. We had observed that CD25 or CD69 were only expressed by a minor fraction of ICOS + cells ( Fig. 1 and data not shown). Thus, we set out experiments to determine whether, despite their distinct characteristics to the above Tr cells, the population of CD4
+ ICOS + cells in the spleen of unmanipulated mice might suppress the proliferation of CD4 + T cells in vitro.
CD4
+ cells were separated into ICOS À and ICOS + subsets by FACS and assayed for proliferation in a standard in vitro Tr assay. The CD4 + ICOS À sub-population proliferated vigorously to anti-CD3 antibody in the presence of T celldepleted, mitomycin C-treated spleen APC (Fig. 3A) . In 
contrast, CD4
+ ICOS + cells were barely activated in this assay and significantly inhibited the proliferation of CD4 +
ICOS
À cells (Fig. 3A) . Similar results were obtained when CD4
+ cells depleted of the CD4 + CD25 + Tr population (CD4 + CD25 À ) were used as responders (Fig. 3B) . Thus, ICOS + lymphocytes suppressed CD4 + T cells proliferation, although they were not as efficient as classical CD4
Trs in inhibiting CD4
+ CD25 À proliferation in this assay (Fig. 3B) . As shown in Fig. 3(C) , only a fraction of CD4 + ICOS + cells were FoxP3 positive, in agreement with the data of CD25 expression (Fig. 1) (Fig. 3A) . These data suggested that the 
CD4 + ICOS + T cells expanded in vitro show a T h 2-and Tr1-biased profile
Using CD4
+ ICOS + cells from the lymph nodes of aged BALB/c mice, Lö hning et al. (20) have shown that antigen activation in vitro yields a population with properties similar to those of the naturally occurring ICOS + population. However, sustained ICOS expression by activated T cells can be observed in BALB/c mice, but not in other strains of mice including C57BL/6 (10), and this might account for some of the functional differences of ICOS in different experimental models. Consequently, we set out experiments to analyze ICOS expression and the lymphokine profile of ICOS À and ICOS + lymphocytes activated and expanded in vitro from strains like B10.BR or C57BL/6, that express lower and transient levels of ICOS upon activation in vitro (10) . CD4 + ICOS À and CD4 + ICOS + were isolated from C57BL/6 by flow cytometry and activated with plate-bound anti-CD3 antibody plus anti-CD28 antibodies. After 72 h, the cells were re-suspended, washed and cultured for further 7 days in fresh medium supplemented with IL-2. The expanded cells were washed again and monitored for ICOS expression and FoxP3 or activated with PDB and ionomycin for 5 h, and their intracellular cytokine content was analyzed. After 10 days of culture, the population derived from ICOS + cells still (Fig. 4B) . Thus, the fraction of IL-10-producing cells was 15-to 100-fold higher among ICOS + descendants (59.0 versus 2.5% in the experiment shown), and the fraction of IL-4-producing cells was 10-to 30-fold higher in ICOS (Fig. 4B and data not shown) , although few among them (<5%) expressed the FoxP3 protein, as shown in Fig. 4(A) .
The presence of pro-inflammatory, IL-17A-producing cells was also checked. About 2% of the expanded ICOS À and 4% of ICOS + cells produced IL-17A (Fig. 4B) . Thus, the ratio of IL-10-to IL-17A-producing cells in the expanded ICOS + cells is >10, whereas the same ratio in the ICOS À population is <2, confirming the anti-inflammatory profile of the ICOS + cells.
ICOS + T cells expanded in vitro suppress CD4 + proliferation
The possibility that the expanded ICOS + population would maintain its suppressive properties was also examined. ICOS À and ICOS + from the spleen of C57BL/6 mice were activated and expanded for 10 days as described above. During this process, the ICOS À population expanded 20-to 25-fold, whereas the ICOS + population expanded 10-to 15-fold (data not shown). The Tr activity of these expanded ICOS À and ICOS + cells (ICOS À and ICOS + in Fig. 5 ) was determined in a classical Tr assay using CD4 +
CD25
À T cells as responders. As shown in Fig. 5 , descendents from ICOS À lymphocytes proliferated moderately when activated with anti-CD3 plus APC and did not significantly inhibit the proliferation of CD4 + CD25 À responder cells. In contrast, the response of ICOS + cells to anti-CD3 plus APC was very low, and these cells produced significant inhibition of CD4 + CD25 À cell proliferation (Fig. 5) .
Transfer of ICOS + T cells reduces EAE susceptibility of ICOSdeficient mice
Given the ability of ICOS + T cells to suppress T cell responses in vitro, we performed experiments to check whether these cells suppressed the development of EAE in vivo, as suggested by the severity of EAE in ICOS-deficient mice (4) or by blockade of ICOS-B7h interactions (15) . ICOS + T cells from wild-type C57BL/6, before or after expansion in vitro (ICOS + and expanded ICOS + , respectively), were injected (3 3 10 6 cells per mouse) into ICOS-deficient female mice (Fig. 6 and Table 1) . After 24 h, the mice were immunized with MOG, and the development of EAE was followed for 30 days. As shown in Fig. 6 , the groups receiving ICOS + cells developed delayed and/or less severe EAE, as determined by the daily average disease score. Delayed EAE was also shown by the significantly higher average day of disease onset for groups receiving ICOS + cells (days 13 and 14.2 for mice receiving ICOS + or expanded ICOS + cells, respectively, versus day 8.8 for the control group, Table 1 ). The lower susceptibility to EAE of mice transferred with ICOS + cells was clearly shown by a lower mean maximal clinical score or by the lower disease index in these mice (Table 1) . In contrast, transfer of ICOS À cells from wild-type mice (ICOS À , Fig. 6 and Table 1 , 15 3 10 6 cells per mouse) produced a more severe EAE, as demonstrated by the enhanced disease index and mean maximal clinical score or the high incidence of deaths in this group.
To determine whether there was a correlation between the cytokine profile and the incidence of EAE, groups of ICOSdeficient mice were injected freshly isolated or in vitro expanded ICOS + cells, and EAE was induced by MOG administration as above. By day 17, control mice developed severe EAE (Fig. 6B, left) , so that the animals were sacrificed. Then, the lymph nodes draining the sites of antigen injection were extracted and their cells activated for 96 h with the immunizing MOG peptide. As shown in Fig. 6(B) , at this time, the EAE score was clearly lower in mice administered ICOS + cells and negligible in mice receiving expanded ICOS + cells (Fig. 6B, left) . The fraction of CD4 + cells in the draining lymph nodes was similar in all the three groups (Fig. 6B, right) , as was the fraction of CD8 + cells or CD3 + cells before or after antigen activation (data not shown). After 4 days of culture, the cells were harvested and the supernatants collected. Then, the cells were further activated for 5 h with phorbol myristate acetate (PMA) plus ionomycin and their intracellular cytokine content was analyzed. As shown in Fig. 6(C) , the percentage of cells producing IFN-c or IL-17A was clearly lower in cultures from mice receiving ICOS + cells, whereas the fraction of IL-4 or IL-10 was similar. The analysis of the supernatants from antigen-activated cultures showed lower levels of IFN-c and particularly IL-17A in supernatants of cultures from mice receiving ICOS + cells and a direct correlation between the EAE scores and the levels of IL-17A in each experimental group (Fig. 6D) . At the same time, there was an inverse correlation between EAE scores and the levels of IL-10 and the T h 2 cytokine IL-5, which were significantly higher in cultures from mice receiving ICOS + cells (Fig. 6D) .
Discussion
The functional properties of CD4 + ICOS + cells present in the spleen of normal mice have been analyzed. CD4
+ ICOS + cells comprise 7-15% of all CD4 + spleen cells from C57BL/ 6, B10.BR or BALB/c mice (Fig. 1) . The level of ICOS expression in freshly extracted CD4 +
ICOS
+ spleen cells from these strains was similar. This is in marked contrast with data showing several-fold differences in ICOS expression among activated cells from BALB/c (high ICOS expression) or C57BL/6 (low ICOS expression) (9, 10) .
This resting ICOS + population has a memory cell phenotype and probably has differentiated from previously activated CD4 + lymphocytes. Since CD28 is needed for optimal ICOS expression upon CD4 + cell activation, the lower number of ICOS + cells in CD28-deficient mice also suggests that, indeed, CD4
+ ICOS + cells might have been previously activated (Fig. 1B) . In the conditions used, CD4
+ ICOS + cells are a prime source of IL-4 and IL-10 and also produce IFNc, whereas the CD4 + ICOS À population efficiently produces IFN-c, but not IL-4 or IL-10 ( Figs 2 and 4) .
Some of the functional characteristics of the CD4 + ICOS (Fig. 2) . Consequently, even though ICOS co-stimulation favors T h 2 differentiation of naive CD4 + T cells (7, 10) or ICOS + cells (Supplementary Figure 3 , available at International Immunology Online), its effect on the bulk of the CD4 + population may initially result in enhanced T h 1 responses, at least in T h 1-prone mouse strains like C57BL/6 or B10.BR. Like CD28, ICOS co-stimulates TCR-mediated activation from its earliest steps (52) and has a broad range of target activation pathways, many of which are common to T h 1 and T h 2 cells (9, 52) , whereas others specifically promote T h 2 differentiation (7, 8) . As ICOS enhances more efficiently T h 2 than T h 1 responses, ICOS co-stimulation might eventually produce T h 2-biased responses. This seems particularly true for the population of CD4 + cells already expressing ICOS + ( Fig. 2 and Supplementary Figure 3 , available at International Immunology Online). Furthermore, our results also indicate that the CD4 + ICOS + population is probably more important to the development of T h 2 responses in genetically T h 1-prone strains like the C57BL/6 or B10.BR mice used in this study than in T h 2-prone strains like BALB/c.
The functional importance of ICOS + cells is stressed by their ability to suppress the proliferation of other CD4
+ cells in Tr assays in vitro (Fig. 3) . These cells maintain their regulatory properties after expansion in vitro (Fig. 5) and do not fit with the phenotype of other recently described ICOS + Tr generated in different models of TCR transgenic mice (22, 23 (Figs 1 and  3) , and they are very difficult to expand in vitro. Rather, the effect of IL-10 blocking antibodies (Fig. 3) and the efficient production of this cytokine by ICOS + cells (Figs 2 and 4 ) suggest an IL-10-mediated suppressor mechanism. Interestingly, ICOS is a marker for germinal center T cells in the mouse (53) , and its suppressive function might be similar to that recently described for human CD4 +
CD57
+ germinal center T h cells (54) .
It has been observed that ICOS-deficient mice develop a more severe EAE to MOG peptide immunization than their wild-type counterparts (4) . Furthermore, ICOS blockade with antibodies during the afferent, induction phase of EAE in SJL mice exacerbated the reaction, whereas ICOS blockade in the efferent, effector phases inhibited the disease (15) . Also, genetic factors regulating the expression level of ICOS . On day 17, after MOG administration, the EAE score was recorded (left), and the percentage of CD4 cells in the draining lymph nodes was determined (right). Data from one experiment of two performed with similar results. *P < 0.05 with data from control mice receiving no ICOS
+ cells (open bars). (C) Lymph node cells from the mice described in (B) were cultured for 96 h in the presence of MOG peptide. Then, the cells were re-stimulated with PMA plus ionomycin for 5 h in the presence of brefeldin A, modulate IL-10 production and susceptibility to EAE in the mouse (55) or multiple sclerosis in humans (56) . Given its suppressive potential in vitro and their anti-inflammatory and T h 2 profile, we hypothesized that the effects observed on the afferent phase of EAE might be due to removal or blockade of the naturally occurring ICOS + population. It should be noted that both Tr and T h 2 cells inhibit the development of EAE (47, 57, 58) . In agreement with this assumption, transfer of either freshly isolated ICOS + spleen cells or of ICOS + spleen cells expanded in vitro clearly reduced the severity of EAE induced by MOG peptide in ICOS-deficient mice ( Fig. 6 and Table 1 ). Interestingly, antigen activation of cells from MOG-immunized ICOS-deficient mice shows that transfer of ICOS + decreased their ability to produce the proinflammatory cytokine IL-17A, while enhancing the secretion of T h 2 or anti-inflammatory cytokines like IL-5 and IL-10 ( Fig.  6 ). Lower IL-17 levels were still detected in the supernatants from antigen-activated cells from mice receiving ICOS + cells remaining on day 44 of treatment in the experiment depicted in Fig. 6(A) (Supplementary Figure 4 , available at International Immunology Online). Recent data have shown a prime role for IL-17 in the development of MOG-induced EAE (59) (60) (61) (62) . ICOS co-stimulation is needed for optimal IL-17 production, as shown by the effect of anti-ICOS antibodies in vitro and IL-17 production by cells from collagen-immunized ICOSko DBA/1 mice upon antigen challenge in vitro (63) . However, ICOS is not essential to IL-17 production, which can be also efficiently produced by cells from ICOS-deficient mice (Fig. 6) . Rather, transfer of ICOS + cells to these mice inhibited IL-17 secretion during EAE induction (Fig. 6) . Intriguingly, IL-17 is important to the development of both EAE and collagen-induced arthritis, yet ICOSko DBA/1 mice are resistant to collagen-induced arthritis, whereas ICOSko C57BL/6 mice have enhanced sensitivity to EAE (4, 63) . Probably, the role of ICOS co-stimulation on other aspects of the immune responses (i.e. in germinal center formation and anti-collagen antibody response) might be essential to the different impact of ICOS deficiency in each model (63, 64 (9, 20) and data not shown]. In summary, the ICOS + cells present in secondary lymphoid organs of normal mice is an effector population whose therapeutic potential in inflammatory diseases needs to be further ascertained. Supplementary Figures 1-4 
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